Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Prothrombin Complex Concentrate Market Size Changed, over the years?

In recent times, the prothrombin complex concentrate market has demonstrated significant growth. It is projected to expand from $1.29 billion in 2024 to $1.39 billion in 2025, with a compound annual growth rate (CAGR) of 7.8%. The growth experienced during the historical period is mainly due to an increased prevalence of bleeding disorders, a rise in the use of warfarin reversal, an enhanced awareness about coagulation therapies, an upsurge in surgical procedures, and a rise in trauma cases.

How Much Will the Prothrombin Complex Concentrate Market Be Worth in 2029?

Anticipations are high for the prothrombin complex concentrate market as it is poised to experience substantial expansion in the upcoming years. The market size is projected to escalate to $1.86 billion in 2029, expanding at a compound annual growth rate (CAGR) of 7.6%. This surge over the forecast period can be associated with the increasing need for quick coagulation treatments, heightened occurrence of hemophilia and liver disorders, growing use in emergency medical care, widening use cases in heart surgeries, and a rise in healthcare spending. The forecast period also unveils major trends such as the use of AI-powered diagnostic tools, progress in recombinant coagulation factors, development of next-gen recombinant pccs, the creation of tailored dosing algorithms, and advancements in blood plasma product technology.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23488&type=smp

Which is the Largest Company in the Prothrombin Complex Concentrate Market?

Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, CSL Behring GmbH, Intas Pharmaceuticals Ltd, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Haemonetics Corporation, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, Emergent BioSolutions, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd (BPL), Prothya Biosolutions B.V., China Biologic Products Holdings Inc.

What Are the Main Market Drivers in the Prothrombin Complex Concentrate Industry?

The prothrombin complex concentrate market’s growth is expected to be stimulated by an upsurge in bleeding disorders. These are conditions where the blood’s ability to clot is impaired, resulting in excessive bleeding due to faulty or absent clotting factors or platelets. The increase in bleeding disorders is predominantly due to the rising occurrence of genetic diseases like hemophilia, ascending liver disease cases, escalating use of anticoagulant drugs, and an elevated incidence of vitamin K shortages. Prothrombin complex concentrate aids in the treatment of these disorders by swiftly restoring clotting factors critical for effective blood coagulation and hemostasis. As an example, a study comprising 10,276 individuals with hemophilia was undertaken across 87 treatment centers in 40 countries according to the U.S.-based National Library of Medicine in November 2023. About half of these participants had severe hemophilia, with 99% being male and 85% diagnosed with hemophilia A. Furthermore, 67% of these patients hailed from low- to middle-income countries. Thus, the escalating prevalence of bleeding disorders is boosting the prothrombin complex concentrate market’s growth. A surge in anticoagulant prescriptions caused by a rising incidence of cardiovascular diseases is anticipated to drive future growth in the prothrombin complex concentrate market. An anticoagulant is a compound that discourages or dilutes clot formation by inhibiting platelet aggregation or coagulation factors. The elevated prescription rate for anticoagulants can be attributed to an increase in cardiovascular diseases, an aging populace, widening clinical signs, enhanced screening protocols, and progress in anticoagulant therapy. Prothrombin complex concentrate counteracts anticoagulants’ effects by quickly replacing clotting factors and reinstating hemostasis in patients with excessive bleeding or immediate surgical needs. For instance, the UK-based National Health Service reported in November 2023 that an additional 460,000 individuals began anticoagulant medication in 2022, leading to over 24 million prescriptions given to patients. This helped prevent an estimated 17,000 strokes and 4,000 deaths. Therefore, the expanding anticoagulant prescription rate is propelling the prothrombin complex concentrate market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23488&type=smp

How Is the Prothrombin Complex Concentrate Market Segments Structured?

The prothrombin complex concentrate market covered in this report is segmented –

1) By Product: 3-Factor Prothrombin Complex Concentrates, 4-Factor Prothrombin Complex Concentrates, Other Products

2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B), Trauma, Life-Threatening Coagulopathy With Acute Bleeding, Warfarin-Associated Acute, Life-Threatening Bleeding, Non-Warfarin Anticoagulant Reversal With Acute Bleeding

3) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular

4) By End-Use: Hospital And Ambulatory Surgical Centers, Specialty Clinics, Other End Users

Subsegments:

1) By Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC), High-Dose 3-Factor Prothrombin Complex Concentrates (PCC), Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)

2) By Type: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC), High-Dose 4-Factor Prothrombin Complex Concentrates (PCC), Activated 4-Factor Prothrombin Complex Concentrates (PCC)

3) By Type: Recombinant Coagulation Factor Complexes, Plasma-Derived Coagulation Factor Complexes, Combination Therapy Products

What Strategic Trends Are Transforming the Prothrombin Complex Concentrate Market?

Noteworthy companies in the prothrombin complex concentrate market are creating novel formulations like lyophilized powder to augment stability, facilitate storage, and make administration easier. Lyophilized powder is a freeze-dried mixture that dehydrates to prolong shelf life and preserve potency. This facilitates improved storage conditions and fast reconstitution for urgent application. For example, in July 2023, Octapharma USA Inc., a biotech company from the US, secured FDA authorization for Balfaxar, a 4-factor prothrombin complex concentrate (4F-PCC) used for immediate warfarin reversal in surgical and invasive processes. The approval arose from the LEX-209 trial, which demonstrated a 94.6% hemostatic efficacy, establishing its effectiveness equivalent to Kcentra. This technological leap highlights the sector’s commitment to the enhancement of coagulation treatments to improve patient results in crucial care situations.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/prothrombin-complex-concentrate-global-market-report

Which Global Regions Offer the Highest Growth in the Prothrombin Complex Concentrate Market?

North America was the largest region in the prothrombin complex concentrate market in 2024. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23488

This Report Delivers Insight On:

1. How big is the prothrombin complex concentrate market, and how is it changing globally?

2. Who are the major companies in the prothrombin complex concentrate market, and how are they performing?

3. What are the key opportunities and risks in the prothrombin complex concentrate market right now?

4. Which products or customer segments are growing the most in the prothrombin complex concentrate market?

5. What factors are helping or slowing down the growth of the prothrombin complex concentrate market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model